Days Sales in Receivables: The average number of days it takes to collect outstanding receivable amounts from customers. Calculated as: Number of Days in Period / Receivable Turnover
Keros Therapeutics, Inc. (KROS) had Days Sales in Receivables of 78.35 for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$18.17M |
|
$-30.70M |
|
-- |
|
$18.17M |
|
$57.98M |
|
$-39.82M |
|
$6.90M |
|
$-32.92M |
|
$-32.92M |
|
$-30.70M |
|
$-30.70M |
|
$-30.70M |
|
$-30.70M |
|
$-39.82M |
|
$-39.45M |
|
40.61M |
|
40.61M |
|
$-0.76 |
|
$-0.76 |
|
| Balance Sheet Financials | |
$732.81M |
|
$4.84M |
|
$24.36M |
|
$757.16M |
|
$34.71M |
|
-- |
|
$15.72M |
|
$50.43M |
|
$706.73M |
|
$706.73M |
|
$706.73M |
|
40.62M |
|
| Cash Flow Statement Financials | |
$131.55M |
|
$-1.28M |
|
$0.02M |
|
$561.38M |
|
$691.66M |
|
$130.28M |
|
$17.41M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.11 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-219.16% |
|
-219.16% |
|
-- |
|
-181.19% |
|
-168.96% |
|
$130.26M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
1.15 |
|
|
Days Sales in Receivables |
78.35 |
-4.34% |
|
-4.34% |
|
-4.05% |
|
-4.34% |
|
$17.40 |
|
$3.21 |
|
$3.24 |
|